Neither 5-Amino-1MQ nor SLU-PP-332 is a peptide, and they do not share a mechanism: 5-Amino-1MQ is a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT), while SLU-PP-332 is an agonist at the estrogen-related receptors ERR alpha, beta and gamma. One removes a methylation sink that competes with NAD-plus salvage; the other switches on a nuclear-receptor transcriptional programme covering mitochondrial biogenesis and oxidative metabolism. In a 5-Amino-1MQ vs SLU-PP-332 comparison, the practical question is whether your model is set up to read enzyme inhibition or transcriptional induction — and whether your solvent system can even handle both.
Both are supplied as lyophilized powder with lot-matched HPLC certificates: 5-Amino-1MQ in 50 mg and 100 mg vials, SLU-PP-332 in 5 mg and 10 mg vials, both listed under fat-loss and metabolic compounds. Both are research chemicals for in-vitro and preclinical laboratory work only, not for human or veterinary use.
5-Amino-1MQ vs SLU-PP-332 at a glance
| Attribute | 5-Amino-1MQ | SLU-PP-332 |
|---|---|---|
| Molecule class | Small molecule — quinolinium salt, not a peptide | Small molecule — synthetic agonist, not a peptide |
| Molecular target | Nicotinamide N-methyltransferase (NNMT), an enzyme | Estrogen-related receptors ERRα, ERRβ, ERRγ — orphan nuclear receptors |
| Mode of action | Enzyme inhibition | Receptor agonism driving transcription |
| CAS number | 42464-96-0 | 2098486-97-2 |
| Molecular weight | 159.21 g/mol | 290.27 g/mol |
| Charge state | Permanently charged cation, supplied as the iodide salt | Neutral, lipophilic |
| Aqueous solubility | Good — the charged core dissolves readily in water | Poor — organic co-solvent such as DMSO is normally required |
| Primary readouts | Intracellular NAD-plus, 1-methylnicotinamide, sirtuin activity, adipocyte lipolysis | PGC-1 target genes, mitochondrial biogenesis markers, oxygen consumption rate, fatty-acid oxidation |
| Tissue focus in the literature | Adipose tissue and liver, where NNMT is highly expressed | Skeletal muscle and heart, where ERR signalling is dominant |
| Evidence level | Cell and rodent studies | Cell and mouse studies; no human evidence |
| Research sizes stocked | 50 mg, 100 mg | 5 mg, 10 mg |
| Purity | ≥99% HPLC, lot-matched COA | ≥99% HPLC, lot-matched COA |
Two different levers on the same broad question
Both compounds are studied because researchers want to manipulate cellular energy metabolism without exercise or caloric restriction as the intervention. That is where the similarity ends.
5-Amino-1MQ: subtracting a methylation sink
NNMT transfers a methyl group from S-adenosylmethionine to nicotinamide, producing 1-methylnicotinamide. The reaction consumes two things at once: a universal methyl donor and a molecule that would otherwise re-enter the NAD-plus salvage pathway. Because NNMT is markedly overexpressed in adipose tissue in obesity models, inhibiting it became an obvious way to test whether that flux is a driver of metabolic slowdown or simply a marker of it. 5-Amino-1MQ is the probe most commonly used for that test, and the readouts follow directly: intracellular NAD-plus, 1-methylnicotinamide levels as a direct product measure, downstream sirtuin activity, and adipocyte lipolysis.
SLU-PP-332: adding a transcriptional programme
The estrogen-related receptors are orphan nuclear receptors that, despite the name, do not bind estradiol — they were named for sequence similarity to the estrogen receptor and act largely through coactivators of the PGC-1 family. They govern much of the transcriptional programme for mitochondrial biogenesis, oxidative phosphorylation and fatty-acid oxidation, particularly in muscle. SLU-PP-332 activates all three subtypes, which is why the literature describes it as an exercise mimetic. That description deserves the caveat the primary reports themselves state: the data are from cell systems and mice, and there is no human evidence.
Why the mechanistic difference changes the experiment
An enzyme inhibitor and a nuclear-receptor agonist operate on different timescales and demand different controls. 5-Amino-1MQ acts on an existing enzyme pool, so metabolite changes can appear within hours and the cleanest confirmation is a direct product measurement — 1-methylnicotinamide should fall if the inhibitor is working. Genetic knockdown of NNMT is the standard orthogonal control, and any effect that survives NNMT knockdown is off-target by definition.
SLU-PP-332 works through transcription, so meaningful readouts require time for messenger RNA and then protein to accumulate; assays sampled too early will show nothing. The appropriate controls are a receptor-level manipulation — ERR knockdown or a selective inverse agonist — rather than a metabolite. Because AMPK and PGC-1 signalling converge on overlapping gene sets, a rise in mitochondrial markers alone does not establish that ERR was the entry point.
These are not interchangeable protocols, and a laboratory that runs one compound on the other's assay schedule will usually conclude, incorrectly, that nothing happened.
Which to choose for which research question
Choose 5-Amino-1MQ for NAD and methylation-flux questions
If the hypothesis concerns NAD-plus availability, methyl-donor economy, sirtuin activity, or the specific role of NNMT in a given tissue, 5-Amino-1MQ is the appropriate chemical probe. It is also the easier compound to deploy in aqueous cell culture, and the 50 mg and 100 mg vial sizes reflect the larger quantities that enzyme-inhibition work typically needs. Groups working on NAD availability from the supply side rather than the sink side often pair it with NAD-plus or NMN as a contrasting approach.
Choose SLU-PP-332 for mitochondrial and oxidative-programme questions
If the question is about mitochondrial biogenesis, oxidative gene expression, respiratory capacity or the transcriptional side of endurance adaptation, SLU-PP-332 is the more direct tool. Muscle and cardiomyocyte systems are its natural setting. A common comparator here is MOTS-c, a mitochondrial-derived peptide studied around overlapping endpoints through an entirely different route, which helps distinguish ERR-specific effects from general metabolic activation.
Run both when the endpoint is shared but the entry point is unknown
Adipocyte and myocyte systems can register both compounds on some shared readouts — oxygen consumption, lipid handling, mitochondrial content. Running them in parallel with their respective orthogonal controls is the standard way to attribute a shared endpoint to one pathway rather than to a general metabolic shift. We also stock a co-formulated SLU-PP-332 with BAM15 preparation for designs pairing ERR agonism with mitochondrial uncoupling, and 5-Amino-1MQ capsules where a fixed unit quantity is more convenient than reconstitution.
Handling, solubility and storage differences
This is where the two diverge most sharply at the bench, and it is the difference most likely to waste material.
5-Amino-1MQ is a permanently charged quinolinium cation supplied as the iodide salt. It dissolves readily in water and aqueous buffer, which makes stock preparation straightforward, but the same permanent charge limits passive membrane crossing — a point worth remembering when an intracellular target is involved and an apparent lack of effect may reflect access rather than potency. The iodide counter-ion also contributes to the labelled mass, so net compound is lower than the vial label suggests.
SLU-PP-332 is a neutral lipophilic small molecule with poor aqueous solubility. It is normally prepared as a concentrated stock in DMSO and diluted into medium immediately before use, with the final solvent concentration kept low and matched in a vehicle control arm. Diluting a DMSO stock too far too fast is a common cause of invisible precipitation, and a compound that has crashed out of solution reads as inactive.
Preparing a concentration is a laboratory calculation, not a recommendation for use: 10 mg of SLU-PP-332 dissolved in 1 mL of DMSO gives 10 mg/mL, which at 290.27 g/mol is approximately 34.4 mM. For 5-Amino-1MQ, 50 mg in 5 mL of water gives 10 mg/mL, approximately 62.8 mM at 159.21 g/mol. Both are stored as sealed vials in the freezer, brought to room temperature before opening, and aliquoted so that stocks are not repeatedly frozen and thawed — see our storage guide.
Purity, identity and COA checks
Small-molecule certificates read differently from peptide certificates. For both compounds ask for HPLC purity with a visible chromatogram and an identity confirmation, and check that the lot number matches the vial. For 5-Amino-1MQ, confirm that the certificate states the salt form, because iodide content materially affects how much active compound a stated mass represents. For SLU-PP-332, residual solvent from synthesis is the more relevant concern, since traces of process solvent can produce effects in sensitive cell assays that have nothing to do with ERR. Our guide to reading a certificate of analysis covers the shared elements.
Regulatory framing
Both compounds are supplied as research chemicals for laboratory use only. Neither is an approved medicine, neither is a dietary supplement, and neither has established human evidence — the SLU-PP-332 record is explicitly limited to cell and mouse work. Nothing on this page is a protocol for human or veterinary use. For where these compounds sit among the broader set of metabolic and mitochondrial research tools, see our energy and mitochondria research overview and our explainer on NNMT as a target.